ArticleFrontiers in oncology2026
Nanoemulsion-enhanced cytotoxicity of
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The pharmacological application of essential oils in cancer therapy is frequently limited by poor bioavailability, physicochemical instability, and insufficient cytotoxic potency. Nano-enabled delivery systems have emerged as pharmacological strategies to enhance the therapeutic performance of natural products; however, their pharmacological mechanisms remain incompletely understood. Methods: We investigated the pharmacological effects of a nanoemulsion incorporating Cyperus scariosus essential oil (NE-CSEO) in human bladder (5637) and lung (A549) cancer cells. Chemical composition was determined by GC-MS, while physicochemical properties were assessed by particle size, polydispersity index, and zeta potential. In vitro cytotoxic effects were evaluated by cell viability assays, and transcriptional responses were explored through gene expression analysis of apoptosis-, antioxidant-, and cell cycle-related genes. Results: NE-CSEO formed a nanoscale emulsion (115 nm) and produced a concentration-dependent reduction in cell viability after 24 h of treatment, with measurable IC50 values of 4.99 ± 0.22 µg/mL and 2.73 ± 0.54 µg/mL in 5637 and A549 cells, respectively, whereas CSEO and NE-B did not reach 50% inhibition within the concentration ranges tested. At the transcriptional level, NE-CSEO increased BAX, CASP3, and CASP9 mRNA expression and decreased BCL2 mRNA expression in both cancer cell models. In bladder cancer cells, NE-CSEO additionally increased p21 mRNA expression and modulated CAT and SOD transcripts. Discussion: These findings indicate that the enhanced in vitro growth-inhibitory activity of NE-CSEO is associated with transcriptional modulation of apoptosis-, antioxidant-, and cell cycle-related genes. However, direct functional confirmation of apoptosis, including protein-level apoptotic signaling and caspase activation, requires further investigation. NE-CSEO provides a basis for further preclinical investigation of nano-enabled natural compounds in cancer models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.